Movement Alert｜Exelixis Intraday Rise 8.26% in Regular Trading, Q3 Earnings Beat and RBC Raises Price Target

Market Focus10-31 00:13

On October 31, Exelixis rose 8.26% in Regular Trading, trading at $71.67/share, with turnover of $113 million.

The move followed a fresh earnings beat and a same-day analyst target increase. Exelixis reported Q3 adjusted EPS of $0.94 on revenue of $658.7 million, up from $0.78 and $597.8 million a year earlier, respectively. Both figures exceeded consensus expectations, while full-year revenue guidance was set at $2.50 billion to $2.55 billion versus a $2.55 billion market estimate.

Separately, RBC raised its price target on Exelixis to $58 from $51 while maintaining a Sector Perform rating. That target revision came after the quarterly release and added support to investor sentiment, even as the company had previously disclosed a three-month FDA review extension for the zanzalintinib plus atezolizumab filing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment